Education Library

Day three highlights from TCT 2022 include several late-breaking trials and interviews with Navin Kapur, MD, and Koichi Toda, MD, PhD.

Adam Salisbury, MD, presents preliminary results from the OPTIMUM Study at TCT 2022.

At TCT 2022, Jonathan Hill, MD, presents the influential high-risk PCI trials shaping the future of ischemic heart failure therapy.

Jonathan Hill, MD, discusses influential trials in high-risk PCI that are shaping the future of ischemic heart failure therapy.

Robert Yeh, MD, discusses how we analyze data, make treatment decisions and participate in developing clinical evidence.

Aditya Bharadwaj, MD, an investigator for the RESTORE EF study, presents a case study epitomizing the results from the trial.

Mitul Patel, MD, discusses the RESTORE EF study and a successful case of improved ejection fraction with complete revascularization.

Jason Wollmuth, MD, describes best practice techniques for Impella-supported complete revascularization in a RESTORE EF case.

Mihas Kodenchery, MD, and Laura Rodriguez, NP, discuss the low mortality and low complication rates in their high-volume high-risk PCI practice.
 

Bobby Yeh, MD, discusses how real-world evidence factors into treatment decisions made every day in clinical practice.

Navin Kapur, MD, discusses the latest science underlying reperfusion and unloading and how it led to the STEMI-DTU pilot and pivotal trials.

Kate Kearney, MD, discusses studies and strategies for revascularization in heart failure with reduced ejection fraction.

Gregg Stone, MD, presents the newly underway PROTECT IV randomized controlled transcatheter heart failure therapy trial at THT 2022.

Mario Iannaccone, MD, discusses his meta-analysis data supporting pre-PCI placement of Impella® for AMI cardiogenic shock.

Alexandra Lansky, MD, discusses a propensity-adjusted population-based analysis of Impella in patients undergoing high-risk PCI from a large-scale claims dataset.